Australia’s Cell and Gene Catalyst calls for Expressions of Interest

Three Expert Working Groups are being established to help support the Cell and Gene Catalyst’s (The Catalyst’s) strategic objectives in key priority areas.

The Catalyst is calling for Expressions of Interest (EOI) from industry professionals interested in supporting key priority areas: policy and advocacy; collaboration and knowledge-sharing; and workforce development.

The Catalyst, a national joint venture between industry peak bodies AusBiotech and Medicines Australia, aims to accelerate the development, manufacture and commercialisation of cell and gene therapies, in turn creating a prosperous cell and gene industry in Australia. It is supported by a steering group comprising Cell Therapies, CSL Behring, Novartis, Pfizer, Roche, and Therapeutic Innovation Australia.

The Catalyst’s vision is that Australian patients have access to world-class advanced therapies while simultaneously cultivating a thriving Australian cell and gene industry. Its mission is to establish an end-to-end value chain for the discovery, development, manufacture and distribution of world-class cell and gene therapies, while promoting job creation, commercialising research, and exporting Australian innovation globally.

A number of strategic priorities have been identified for the Catalyst, with four key areas of focus. These are: attracting, building, and retaining world-class talent; fostering collaboration and knowledge sharing; creating a clear regulatory and market access pathway; and building Australian capability across the entire value chain.

Members of the Expert Working Groups will be immersed within a network of change-makers and leaders within Australia’s cell and gene industry across the entire value chain. Importantly, the Expert Working Groups will be an active contribution to this rapidly growing sector which will positively impact Australia’s health and economy.

Successful applicants are required to volunteer approximately two to three hours each month during 2024 in support of the Catalyst’s goals and activities.

/Public Release. View in full here.